Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)
The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
Objective This multicenter, treat-to-target, phase 3 trial evaluated the efficacy and safety of fast-acting insulin aspart (faster aspart) versus conventional insulin aspart (IAsp) in adults with type 1 diabetes. Research design and methods The primary end point was change from baseline in HbA 1c after 26 weeks. After an 8-week run-in, subjects were randomized (1:1:1) to double-blind mealtime faster aspart ( n = 381), IAsp ( n = 380), or open-label postmeal faster aspart ( n = 382)-each with insulin detemir. Results HbA 1c was reduced in both treatment groups, and noninferiority to IAsp was confirmed for both mealtime and postmeal faster aspart (estimated treatment difference [ETD] faster aspart-IAsp, mealtime, -0.15% [95% CI -0.23; -0.07], and postmeal, 0.04% [-0.04; 0.12]); mealtime faster aspart statistically significantly reduced HbA 1c versus IAsp ( P = 0.0003). Postprandial plasma glucose (PPG) increments were statistically significantly lower with mealtime faster aspart at 1 h (ETD -1.18 mmol/L [95% CI -1.65; -0.71], -21.21 mg/dL [-29.65; -12.77]; P P = 0.0375) after the meal test; superiority to IAsp for the 2-h PPG increment was confirmed. The overall rate of severe or blood glucose-confirmed (plasma glucose Conclusions Faster aspart effectively improved HbA 1c , and noninferiority to IAsp was confirmed, with superior PPG control for mealtime faster aspart versus IAsp. Subjects randomized to postmeal faster aspart for all meals maintained HbA 1c noninferior to that o…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are limited data comparing the latest basal insulin analogs degludec and glargine U300.1147,1148”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1148]
In the citing paper
“Results from comparative effectiveness meta-analyses suggest that each new class of oral noninsulin agents when added to metformin generally lowers A1C by approximately 0.7-1.0%(8-11 mmol/mol).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [11]
Citations
Cites
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Andrea, D., Kakuk, P., & Judit, S. (2014) · University of Debrecen Electronic Archive (University of Debrecen) · Cited by 1,954
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Long-Term Complications of Diabetes Mellitus
Nathan, D. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306103282306 · Cited by 1,495
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“Severe hypoglycemia was defined according to the American Diabetes Association classification (26) and BG-confirmed hypoglycemia by a PG value ,3.”
MethodSelf-citationPeyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655 · cited 1×
“4%) of people with diabetes would like their insulin regimen to fit with their daily life changes (23), and the option to take their insulin dose after a meal when necessary may address this need.”
BackgroundFrost, G. I. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.427 · Cited by 323
Home, P. D., Lindholm, A., Riis, A., & for the European Insulin Aspart Study Group (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00380.x · Cited by 232
Raskin, P., Guthrie, R. A., Leiter, L., Riis, A., & Jovanovic, L. (2000) · Diabetes Care · doi:10.2337/diacare.23.5.583 · Cited by 230
Research works printed but not linked: 5
- Andersen, 2015, Ultra-rapid BioChaperone insulin Lispro (BC-LIS): linear dose-response and faster absorption than insulin Lispro (LIS), Diabetologia, 58, S449
- Hirsch, 2014, Recombinant human hyaluronidase pretreatment of CSII cannula sites provides comparable glycemic control with reduced hypoglycemia in T1DM compared to usual CSII, Diabetes, 63, 85-LB
- Høiberg-Nielsen, 2016, Mechanistic analysis into the mode of action of niacinamide in faster-acting insulin aspart, Diabetes Technol Ther, 18, A291
- Rodbard, 2016, Adding faster-acting insulin aspart to basal insulin significantly improved glycemic control: the onset 3 trial, Diabetes, 65, A64
- 2016, Compatibility and safety of faster-acting insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes, Endocr Rev, 37, FRI697
Cited by
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Metadata
- Authors
- Russell-Jones, D., Bode, B. W., De Block, C., Franek, E., Heller, S. R., Mathieu, C., Philis-Tsimikas, A., Rose, L., Woo, V. C., Østerskov, A. B., Graungaard, T., & Bergenstal, R. M.
- Affiliations
- Royal Surrey County Hospital (GB)
- Atlanta Diabetes Associates (US)
- Department of Endocrinology, Diabetology, and Metabolism, Antwerp University Hospital, Antwerp, Belgium
- Mossakowski Medical Research Institute, Polish Academy of Sciences (PL)
- University of Sheffield (GB)
- Universitair Ziekenhuis Leuven (BE)
- Scripps Whittier Diabetes Institute, Scripps Health, San Diego, CA
- Institute of Diabetes Research, Münster, Germany
- University of Manitoba (CA)
- Novo Nordisk (Denmark) (DK)
- Park Nicollet Health Services (US)
- Corresponding author
- Russell-Jones, David
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-03-29
- Volume
- 40
- Issue
- 7
- Pages
- 943-950
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2598553007
- Cited by
- 177
- References
- 23
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 21 · 2021: 22 · 2020: 23 · 2019: 22 · 2018: 35 · 2017: 14
- FWCI
- 20.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- fast-acting insulin aspart, insulin aspart, type 1 diabetes, multiple daily insulin injections, insulin detemir, glycemic control, HbA1c, postprandial blood glucose, hypoglycemia, non-inferiority, mealtime insulin, insulin analogues, treat-to-target, adults with type 1 diabetes
- MeSH terms
- Insulin Detemir, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Male, Middle Aged, Body Mass Index, Postprandial Period, Endpoint Determination, Insulin Aspart, Meals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1). https://app.cochat.ai/papers/10.2337/dc16-1771
- The paper
- Russell-Jones, D., Bode, B. W., De Block, C., Franek, E., Heller, S. R., Mathieu, C., Philis-Tsimikas, A., Rose, L., Woo, V. C., Østerskov, A. B., Graungaard, T., & Bergenstal, R. M. (2017). Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1). Diabetes Care. https://doi.org/10.2337/dc16-1771
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.